Autism Studies and Related Medical Conditions, January 2009 - TACA

increased risks for neurodevelopmental disorders following additional doses of
thimerosal... The following are [sic] a brief sampling of some of effects observed:"
autism = 7.62 (95% Confidence Interval (CI) = 1.84-31.5)
autism = 11.35 (95% CI = 2.70-47.76)
specific disorders of sleep of non-organic origin = 4.98 (95% CI = 1.55-15.94)
specific disorders of sleep of non-organic origin = 4.64 (95% CI = 1.12-19.25)
phase-disruption of 24-hour sleep-wake cycle = 53.64 (95% CI = 3.23-892.10)
somnambulism or night terrors = 5.76 (95% CI = 1.38-24.05)
attention deficit without mention of hyperactivity = 6.38 (95% CI = 1.56-26.09)
attention deficit with mention of hyperactivity = 8.29 (95% CI = 2.03-33.89)
developmental speech or language disorder = 2.09 (95% CI = 1.08-4.03)
other developmental speech or language delay = 2.32 (95% CI = 1.20-4.48)
unspecified delay in development = 2.08 (95% CI = 1.03-4.19)
[the above data] among children receiving > 25 micrograms ethylmercury from
thimerosal at age 1 month in comparison to children receiving 0 micrograms of
ethylmercury at age 1 month;
attention deficit disorder = 2.88 (95% CI = 1.05-7.88) and
attention deficit disorder = 2.84 (95% CI = 1.03-7.85), and
coordination disorder = 18.26 (95% CI = 5.65-59.01)
among children receiving > 75 micrograms of ethylmercury from thimerosal in
comparison to children receiving < 12.5 microgram from thimerosal at age 3 months;
and
autism = 2.15 (95% CI = 1.04-4.43) and
among children receiving increases of 7.5-10 micrograms of thimerosal over 1 month, in
comparison to children receiving less than 5 micrograms of ethylmercury from
thimerosal over 1 month [9-10].
"Additionally, studies were conducted in 2000 by CDC to evaluate the dose-response
effects of thimerosal on childhood neurodevelopmental disorders based upon evaluation
of the VSD database [11]. It was found that there were statistically significant
relationships between increasing exposures to thimerosal and the following
outcomes, including:
(1) for two months of age, an unspecified developmental delay, which has its own ICD-
9 code.
(2) Exposure at three months of age, Tics.
(3) Exposure at six months of age, language and speech delays, which are two separate
ICD-9 codes.
(4) Exposure at one, three and six months of age, the entire category of
Autism Studies & Related Medical Conditions – TACA © Page 308